Inmed Pharmaceuticals Stock Fundamentals
InMed Pharmaceuticals fundamentals help investors to digest information that contributes to InMed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of InMed OTC Stock. The fundamental analysis module provides a way to measure InMed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to InMed Pharmaceuticals otc stock.
InMed |
InMed Pharmaceuticals OTC Stock Current Valuation Analysis
InMed Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current InMed Pharmaceuticals Current Valuation | 35.74 M |
Most of InMed Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InMed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, InMed Pharmaceuticals has a Current Valuation of 35.74 M. This is 99.75% lower than that of the Healthcare sector and 99.23% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.79% higher than that of the company.
InMed Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining InMed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare InMed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across InMed Pharmaceuticals competition to find correlations between indicators driving InMed Pharmaceuticals's intrinsic value. More Info.InMed Pharmaceuticals is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value InMed Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for InMed Pharmaceuticals' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the InMed Pharmaceuticals' earnings, one of the primary drivers of an investment's value.InMed Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InMed Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of InMed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing InMed Pharmaceuticals by comparing valuation metrics of similar companies.InMed Pharmaceuticals is currently under evaluation in current valuation category among related companies.
InMed Fundamentals
| Return On Equity | -91.74 | |||
| Return On Asset | -50.41 | |||
| Current Valuation | 35.74 M | |||
| Shares Outstanding | 158.2 K | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Earning | (11.11) X | |||
| Price To Book | 60.57 X | |||
| EBITDA | (7.19 M) | |||
| Net Income | (7.17 M) | |||
| Cash And Equivalents | 18.58 M | |||
| Cash Per Share | 0.11 X | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 3.77 X | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (3.79 M) | |||
| Earnings Per Share | (0.05) X | |||
| Beta | 2.55 | |||
| Market Capitalization | 35.1 M | |||
| Total Asset | 1.21 M | |||
| Retained Earnings | (29.51 M) | |||
| Working Capital | (309 K) | |||
| Current Asset | 145 K | |||
| Current Liabilities | 454 K | |||
| Z Score | -50.1 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards InMed Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, InMed Pharmaceuticals' short interest history, or implied volatility extrapolated from InMed Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the InMed Pharmaceuticals information on this page should be used as a complementary analysis to other InMed Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in InMed OTC Stock
If you are still planning to invest in InMed Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InMed Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |